Cargando…

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates...

Descripción completa

Detalles Bibliográficos
Autores principales: Lux, Michael P., Hartkopf, Andreas D., Fehm, Tanja N., Welslau, Manfred, Müller, Volkmar, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Witzel, Isabell, Thomssen, Christoph, Beierlein, Milena, Belleville, Erik, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Aktas, Bahriye, Banys-Paluchowski, Maggie, Kolberg-Liedtke, Cornelia, Wöckel, Achim, Kolberg, Hans-Christian, Harbeck, Nadia, Bartsch, Rupert, Schneeweiss, Andreas, Ettl, Johannes, Würstlein, Rachel, Krug, David, Taran, Florin-Andrei, Lüftner, Diana, Stickeler, Elmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617389/
https://www.ncbi.nlm.nih.gov/pubmed/37916184
http://dx.doi.org/10.1055/a-2074-0125
_version_ 1785129597374824448
author Lux, Michael P.
Hartkopf, Andreas D.
Fehm, Tanja N.
Welslau, Manfred
Müller, Volkmar
Schütz, Florian
Fasching, Peter A.
Janni, Wolfgang
Witzel, Isabell
Thomssen, Christoph
Beierlein, Milena
Belleville, Erik
Untch, Michael
Thill, Marc
Tesch, Hans
Ditsch, Nina
Aktas, Bahriye
Banys-Paluchowski, Maggie
Kolberg-Liedtke, Cornelia
Wöckel, Achim
Kolberg, Hans-Christian
Harbeck, Nadia
Bartsch, Rupert
Schneeweiss, Andreas
Ettl, Johannes
Würstlein, Rachel
Krug, David
Taran, Florin-Andrei
Lüftner, Diana
Stickeler, Elmar
author_facet Lux, Michael P.
Hartkopf, Andreas D.
Fehm, Tanja N.
Welslau, Manfred
Müller, Volkmar
Schütz, Florian
Fasching, Peter A.
Janni, Wolfgang
Witzel, Isabell
Thomssen, Christoph
Beierlein, Milena
Belleville, Erik
Untch, Michael
Thill, Marc
Tesch, Hans
Ditsch, Nina
Aktas, Bahriye
Banys-Paluchowski, Maggie
Kolberg-Liedtke, Cornelia
Wöckel, Achim
Kolberg, Hans-Christian
Harbeck, Nadia
Bartsch, Rupert
Schneeweiss, Andreas
Ettl, Johannes
Würstlein, Rachel
Krug, David
Taran, Florin-Andrei
Lüftner, Diana
Stickeler, Elmar
author_sort Lux, Michael P.
collection PubMed
description In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.
format Online
Article
Text
id pubmed-10617389
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-106173892023-11-01 Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer Lux, Michael P. Hartkopf, Andreas D. Fehm, Tanja N. Welslau, Manfred Müller, Volkmar Schütz, Florian Fasching, Peter A. Janni, Wolfgang Witzel, Isabell Thomssen, Christoph Beierlein, Milena Belleville, Erik Untch, Michael Thill, Marc Tesch, Hans Ditsch, Nina Aktas, Bahriye Banys-Paluchowski, Maggie Kolberg-Liedtke, Cornelia Wöckel, Achim Kolberg, Hans-Christian Harbeck, Nadia Bartsch, Rupert Schneeweiss, Andreas Ettl, Johannes Würstlein, Rachel Krug, David Taran, Florin-Andrei Lüftner, Diana Stickeler, Elmar Geburtshilfe Frauenheilkd In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results. Georg Thieme Verlag KG 2023-06-06 /pmc/articles/PMC10617389/ /pubmed/37916184 http://dx.doi.org/10.1055/a-2074-0125 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Lux, Michael P.
Hartkopf, Andreas D.
Fehm, Tanja N.
Welslau, Manfred
Müller, Volkmar
Schütz, Florian
Fasching, Peter A.
Janni, Wolfgang
Witzel, Isabell
Thomssen, Christoph
Beierlein, Milena
Belleville, Erik
Untch, Michael
Thill, Marc
Tesch, Hans
Ditsch, Nina
Aktas, Bahriye
Banys-Paluchowski, Maggie
Kolberg-Liedtke, Cornelia
Wöckel, Achim
Kolberg, Hans-Christian
Harbeck, Nadia
Bartsch, Rupert
Schneeweiss, Andreas
Ettl, Johannes
Würstlein, Rachel
Krug, David
Taran, Florin-Andrei
Lüftner, Diana
Stickeler, Elmar
Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
title Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
title_full Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
title_fullStr Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
title_full_unstemmed Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
title_short Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
title_sort update breast cancer 2023 part 2 – advanced-stage breast cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617389/
https://www.ncbi.nlm.nih.gov/pubmed/37916184
http://dx.doi.org/10.1055/a-2074-0125
work_keys_str_mv AT luxmichaelp updatebreastcancer2023part2advancedstagebreastcancer
AT hartkopfandreasd updatebreastcancer2023part2advancedstagebreastcancer
AT fehmtanjan updatebreastcancer2023part2advancedstagebreastcancer
AT welslaumanfred updatebreastcancer2023part2advancedstagebreastcancer
AT mullervolkmar updatebreastcancer2023part2advancedstagebreastcancer
AT schutzflorian updatebreastcancer2023part2advancedstagebreastcancer
AT faschingpetera updatebreastcancer2023part2advancedstagebreastcancer
AT janniwolfgang updatebreastcancer2023part2advancedstagebreastcancer
AT witzelisabell updatebreastcancer2023part2advancedstagebreastcancer
AT thomssenchristoph updatebreastcancer2023part2advancedstagebreastcancer
AT beierleinmilena updatebreastcancer2023part2advancedstagebreastcancer
AT bellevilleerik updatebreastcancer2023part2advancedstagebreastcancer
AT untchmichael updatebreastcancer2023part2advancedstagebreastcancer
AT thillmarc updatebreastcancer2023part2advancedstagebreastcancer
AT teschhans updatebreastcancer2023part2advancedstagebreastcancer
AT ditschnina updatebreastcancer2023part2advancedstagebreastcancer
AT aktasbahriye updatebreastcancer2023part2advancedstagebreastcancer
AT banyspaluchowskimaggie updatebreastcancer2023part2advancedstagebreastcancer
AT kolbergliedtkecornelia updatebreastcancer2023part2advancedstagebreastcancer
AT wockelachim updatebreastcancer2023part2advancedstagebreastcancer
AT kolberghanschristian updatebreastcancer2023part2advancedstagebreastcancer
AT harbecknadia updatebreastcancer2023part2advancedstagebreastcancer
AT bartschrupert updatebreastcancer2023part2advancedstagebreastcancer
AT schneeweissandreas updatebreastcancer2023part2advancedstagebreastcancer
AT ettljohannes updatebreastcancer2023part2advancedstagebreastcancer
AT wurstleinrachel updatebreastcancer2023part2advancedstagebreastcancer
AT krugdavid updatebreastcancer2023part2advancedstagebreastcancer
AT taranflorinandrei updatebreastcancer2023part2advancedstagebreastcancer
AT luftnerdiana updatebreastcancer2023part2advancedstagebreastcancer
AT stickelerelmar updatebreastcancer2023part2advancedstagebreastcancer